6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
label O
: O
* O
Infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
[ O
See O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.1 O
) O
. O
] O

* O
Cardiopulmonary B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
[ O
See O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.2 O
) O
. O
] O

* O
Pulmonary B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
[ O
See O
Warnings O
and O
Precautions O
( O
5.3 O
) O
. O
] O

* O
Dermatologic B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
[ O
See O
Warnings O
and O
Precautions O
( O
5.4 O
) O
. O
] O

* O
Hypomagnesemia B-OSE_Labeled_AE
and O
Electrolyte B-OSE_Labeled_AE
Abnormalities I-OSE_Labeled_AE
[ O
See O
Warnings O
and O
Precautions O
( O
5.6 O
) O
. O
] O

The O
most O
common O
adverse O
reactions O
in O
Erbitux O
clinical O
trials O
( O
incidence O
> O
=25 O
% O
) O
include O
cutaneous B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
including O
rash B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
and O
nail B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
) O
, O
headache B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
and O
infection B-OSE_Labeled_AE
. O

The O
most O
serious O
adverse O
reactions O
with O
Erbitux O
are O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
cardiopulmonary B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
dermatologic B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
and O
radiation B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
and O
pulmonary B-OSE_Labeled_AE
embolus I-OSE_Labeled_AE
. O

Across O
Studies O
1 O
, O
3 O
, O
5 O
, O
and O
6 O
, O
Erbitux O
was O
discontinued O
in O
3-10 O
% O
of O
patients O
because O
of O
adverse O
reactions O
. O

EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
=25 O
% O
) O
are O
: O
cutaneous O
adverse O
reactions O
( O
including O
rash O
, O
pruritus O
, O
and O
nail O
changes O
) O
, O
headache O
, O
diarrhea O
, O
and O
infection O
. O

( O
6 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Eli O
Lilly O
and O
Company O
at O
1-800-LillyRx O
( O
1-800-545-5979 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
data O
below O
reflect O
exposure O
to O
Erbitux O
in O
1373 O
patients O
with O
SCCHN B-Not_AE_Candidate
or O
colorectal B-Not_AE_Candidate
cancer I-Not_AE_Candidate
in O
randomized O
Phase O
3 O
( O
Studies O
1 O
and O
5 O
) O
or O
Phase O
2 O
( O
Studies O
3 O
and O
6 O
) O
trials O
treated O
at O
the O
recommended O
dose O
and O
schedule O
for O
medians O
of O
7 O
to O
14 O
weeks O
. O

[ O
See O
Clinical O
Studies O
( O
14 O
) O
. O
] O

Infusion B-NonOSE_AE
reactions I-NonOSE_AE
: O
Infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
which O
included O
pyrexia B-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
rigors B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
bronchospasm B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
and O
hypotension B-OSE_Labeled_AE
occurred O
in O
15-21 O
% O
of O
patients O
across O
studies O
. O

Grades O
3 O
and O
4 O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
occurred O
in O
2-5 O
% O
of O
patients O
; O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
were O
fatal B-NonOSE_AE
in O
1 O
patient O
. O

Infections B-NonOSE_AE
: O
The O
incidence O
of O
infection B-OSE_Labeled_AE
was O
variable O
across O
studies O
, O
ranging O
from O
13-35 O
% O
. O

Sepsis B-OSE_Labeled_AE
occurred O
in O
1-4 O
% O
of O
patients O
. O

Renal B-NonOSE_AE
: O
Renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
occurred O
in O
1 O
% O
of O
patients O
with O
colorectal B-Not_AE_Candidate
cancer I-Not_AE_Candidate
. O

Squamous O
Cell O
Carcinoma O
of O
the O
Head O
and O
Neck O
Erbitux O
in O
Combination O
with O
Radiation O
Therapy O
Table O
2 O
contains O
selected O
adverse O
reactions O
in O
420 O
patients O
receiving O
radiation O
therapy O
either O
alone O
or O
with O
Erbitux O
for O
locally O
or O
regionally O
advanced O
SCCHN B-Not_AE_Candidate
in O
Study O
1 O
. O

Erbitux O
was O
administered O
at O
the O
recommended O
dose O
and O
schedule O
( O
400 O
mg/m O
2 O
initial O
dose O
, O
followed O
by O
250 O
mg/m O
2 O
weekly O
) O
. O

Patients O
received O
a O
median O
of O
8 O
infusions O
( O
range O
1-11 O
) O
. O

Table O
2 O
: O
Incidence O
of O
Selected O
Adverse O
Reactions O
( O
> O
=10 O
% O
) O
in O
Patients O
with O
Locoregionally O
Advanced O
SCCHN O
Body O
System O
Preferred O
Term O
Erbitux O
plus O
Radiation O
( O
n=208 O
) O
Radiation O
Therapy O
Alone O
( O
n=212 O
) O
Grades O
1-4 O
Grades O
3 O
and O
4 O
Grades O
1-4 O
Grades O
3 O
and O
4 O
% O
of O
Patients O
a O
Includes O
cases O
also O
reported O
as O
infusion B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
. O

b O
Infusion B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
is O
defined O
as O
any O
event O
described O
at O
any O
time O
during O
the O
clinical O
study O
as O
`` O
allergic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
`` O
or O
`` O
anaphylactoid B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
`` O
, O
or O
any O
event O
occurring O
on O
the O
first O
day O
of O
dosing O
described O
as O
`` O
allergic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
`` O
, O
`` O
anaphylactoid B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
`` O
, O
`` O
fever B-OSE_Labeled_AE
`` O
, O
`` O
chills B-OSE_Labeled_AE
`` O
, O
`` O
chills B-OSE_Labeled_AE
and I-OSE_Labeled_AE
fever I-OSE_Labeled_AE
`` O
, O
or O
`` O
dyspnea B-OSE_Labeled_AE
`` O
. O

c O
Based O
on O
laboratory O
measurements O
, O
not O
on O
reported O
adverse O
reactions O
, O
the O
number O
of O
subjects O
with O
tested O
samples O
varied O
from O
205-206 O
for O
Erbitux O
plus O
Radiation O
arm O
; O
209-210 O
for O
Radiation O
alone O
. O

d O
Acneiform B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
is O
defined O
as O
any O
event O
described O
as O
`` O
acne B-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
`` O
, O
`` O
maculopapular B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
`` O
, O
`` O
pustular B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
`` O
, O
`` O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
`` O
, O
or O
`` O
exfoliative B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
`` O
. O

Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
Asthenia B-OSE_Labeled_AE
56 O
4 O
49 O
5 O
Fever B-OSE_Labeled_AE
a O
29 O
1 O
13 O
1 O
Headache B-OSE_Labeled_AE
19 O
< O
1 O
8 O
< O
1 O
Infusion B-OSE_Labeled_AE
Reaction I-OSE_Labeled_AE
b O
15 O
3 O
2 O
0 O
Infection B-OSE_Labeled_AE
13 O
1 O
9 O
1 O
Chills B-OSE_Labeled_AE
a O
16 O
0 O
5 O
0 O
Digestive B-NonOSE_AE
Nausea B-OSE_Labeled_AE
49 O
2 O
37 O
2 O
Emesis B-OSE_Labeled_AE
29 O
2 O
23 O
4 O
Diarrhea B-OSE_Labeled_AE
19 O
2 O
13 O
1 O
Dyspepsia B-OSE_Labeled_AE
14 O
0 O
9 O
1 O
Metabolic B-NonOSE_AE
/ I-NonOSE_AE
Nutritional I-NonOSE_AE
Weight B-OSE_Labeled_AE
Loss I-OSE_Labeled_AE
84 O
11 O
72 O
7 O
Dehydration B-OSE_Labeled_AE
25 O
6 O
19 O
8 O
Alanine B-OSE_Labeled_AE
Transaminase I-OSE_Labeled_AE
, I-OSE_Labeled_AE
high I-OSE_Labeled_AE
c O
43 O
2 O
21 O
1 O
Aspartate B-OSE_Labeled_AE
Transaminase I-OSE_Labeled_AE
, I-OSE_Labeled_AE
high I-OSE_Labeled_AE
c O
38 O
1 O
24 O
1 O
Alkaline B-OSE_Labeled_AE
Phosphatase I-OSE_Labeled_AE
, I-OSE_Labeled_AE
high I-OSE_Labeled_AE
c O
33 O
< O
1 O
24 O
0 O
Respiratory B-NonOSE_AE
Pharyngitis B-OSE_Labeled_AE
26 O
3 O
19 O
4 O
Skin B-NonOSE_AE
/ I-NonOSE_AE
Appendages I-NonOSE_AE
Acneiform B-OSE_Labeled_AE
Rash I-OSE_Labeled_AE
d O
87 O
17 O
10 O
1 O
Radiation B-OSE_Labeled_AE
Dermatitis I-OSE_Labeled_AE
86 O
23 O
90 O
18 O
Application B-OSE_Labeled_AE
Site I-OSE_Labeled_AE
Reaction I-OSE_Labeled_AE
18 O
0 O
12 O
1 O
Pruritus B-OSE_Labeled_AE
16 O
0 O
4 O
0 O
The O
incidence O
and O
severity O
of O
mucositis B-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
and O
xerostomia B-OSE_Labeled_AE
were O
similar O
in O
both O
arms O
of O
the O
study O
. O

Late O
Radiation O
Toxicity O
The O
overall O
incidence O
of O
late B-OSE_Labeled_AE
radiation I-OSE_Labeled_AE
toxicities I-OSE_Labeled_AE
( O
any O
grade O
) O
was O
higher O
in O
Erbitux O
in O
combination O
with O
radiation O
therapy O
compared O
with O
radiation O
therapy O
alone O
. O

The O
following O
sites O
were O
affected O
: O
salivary O
glands O
( O
65 O
% O
versus O
56 O
% O
) O
, O
larynx O
( O
52 O
% O
versus O
36 O
% O
) O
, O
subcutaneous O
tissue O
( O
49 O
% O
versus O
45 O
% O
) O
, O
mucous O
membrane O
( O
48 O
% O
versus O
39 O
% O
) O
, O
esophagus O
( O
44 O
% O
versus O
35 O
% O
) O
, O
skin O
( O
42 O
% O
versus O
33 O
% O
) O
. O

The O
incidence O
of O
Grade O
3 O
or O
4 O
late B-NonOSE_AE
radiation I-NonOSE_AE
toxicities I-NonOSE_AE
was O
similar O
between O
the O
radiation O
therapy O
alone O
and O
the O
Erbitux O
plus O
radiation O
treatment O
groups O
. O

Study O
2 O
: O
EU-Approved O
Cetuximab O
in O
Combination O
with O
Platinum-based O
Therapy O
with O
5-Fluorouracil O
Study O
2 O
used O
EU-approved O
cetuximab O
. O

Since O
U.S.-licensed O
Erbitux O
provides O
approximately O
22 O
% O
higher O
exposure O
relative O
to O
the O
EU-approved O
cetuximab O
, O
the O
data O
provided O
below O
may O
underestimate O
the O
incidence O
and O
severity O
of O
adverse O
reactions O
anticipated O
with O
Erbitux O
for O
this O
indication O
. O

However O
, O
the O
tolerability O
of O
the O
recommended O
dose O
is O
supported O
by O
safety O
data O
from O
additional O
studies O
of O
Erbitux O
[ O
see O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

Table O
3 O
contains O
selected O
adverse O
reactions O
in O
434 O
patients O
with O
recurrent O
locoregional O
disease O
or O
metastatic O
SCCHN B-Not_AE_Candidate
receiving O
EU-approved O
cetuximab O
in O
combination O
with O
platinum-based O
therapy O
with O
5-FU O
or O
platinum-based O
therapy O
with O
5-FU O
alone O
in O
Study O
2 O
. O

Cetuximab O
was O
administered O
at O
400 O
mg/m O
2 O
for O
the O
initial O
dose O
, O
followed O
by O
250 O
mg/m O
2 O
weekly O
. O

Patients O
received O
a O
median O
of O
17 O
infusions O
( O
range O
1-89 O
) O
. O

Table O
3 O
: O
Incidence O
of O
Selected O
Adverse O
Reactions O
( O
> O
=10 O
% O
) O
in O
Patients O
with O
Recurrent O
Locoregional O
Disease O
or O
Metastatic O
SCCHN O
System O
Organ O
Class O
Preferred O
Term O
EU-Approved O
Cetuximab O
plus O
Platinum-based O
Therapy O
with O
5-FU O
( O
n=219 O
) O
Platinum-based O
Therapy O
with O
5-FU O
Alone O
( O
n=215 O
) O
Grades O
1-4 O
Grades O
3 O
and O
4 O
Grades O
1-4 O
Grades O
3 O
and O
4 O
% O
of O
Patients O
a O
Infusion B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
defined O
as O
any O
event O
of O
`` O
anaphylactic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
`` O
, O
`` O
hypersensitivity B-OSE_Labeled_AE
`` O
, O
`` O
fever B-OSE_Labeled_AE
and/or O
chills B-OSE_Labeled_AE
`` O
, O
`` O
dyspnea B-OSE_Labeled_AE
`` O
, O
or O
`` O
pyrexia B-OSE_Labeled_AE
`` O
on O
the O
first O
day O
of O
dosing O
. O

b O
Infection B-OSE_Labeled_AE
- O
this O
term O
excludes O
sepsis B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
events O
which O
are O
presented O
separately O
. O

c O
Acneiform B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
defined O
as O
any O
event O
described O
as O
`` O
acne B-OSE_Labeled_AE
`` O
, O
`` O
dermatitis B-OSE_Labeled_AE
acneiform I-OSE_Labeled_AE
`` O
, O
`` O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
`` O
, O
`` O
exfoliative B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
erythematous I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
macular I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
papular I-OSE_Labeled_AE
`` O
, O
or O
`` O
rash B-OSE_Labeled_AE
pustular I-OSE_Labeled_AE
`` O
.Chemotherapy O
= O
cisplatin O
+ O
5-fluorouracil O
or O
carboplatin O
+ O
5-fluorouracil O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
Conjunctivitis B-OSE_Labeled_AE
10 O
0 O
0 O
0 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
54 O
4 O
47 O
4 O
Diarrhea B-OSE_Labeled_AE
26 O
5 O
16 O
1 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
Pyrexia B-OSE_Labeled_AE
22 O
0 O
13 O
1 O
Infusion B-OSE_Labeled_AE
Reactiona I-OSE_Labeled_AE
10 O
2 O
< O
1 O
0 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Infection B-OSE_Labeled_AE
b O
44 O
11 O
27 O
8 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Anorexia B-OSE_Labeled_AE
25 O
5 O
14 O
1 O
Hypocalcemia B-OSE_Labeled_AE
12 O
4 O
5 O
1 O
Hypokalemia B-OSE_Labeled_AE
12 O
7 O
7 O
5 O
Hypomagnesemia B-OSE_Labeled_AE
11 O
5 O
5 O
1 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Acneiform B-OSE_Labeled_AE
Rash I-OSE_Labeled_AE
c O
70 O
9 O
2 O
0 O
Rash B-OSE_Labeled_AE
28 O
5 O
2 O
0 O
Acne B-OSE_Labeled_AE
22 O
2 O
0 O
0 O
Dermatitis B-OSE_Labeled_AE
Acneiform I-OSE_Labeled_AE
15 O
2 O
0 O
0 O
Dry B-OSE_Labeled_AE
Skin I-OSE_Labeled_AE
14 O
0 O
< O
1 O
0 O
Alopecia B-OSE_Labeled_AE
12 O
0 O
7 O
0 O
For O
cardiac B-NonOSE_AE
disorders I-NonOSE_AE
, O
approximately O
9 O
% O
of O
subjects O
in O
both O
the O
EU-approved O
cetuximab O
plus O
chemotherapy O
and O
chemotherapy-only O
treatment O
arms O
in O
Study O
2 O
experienced O
a O
cardiac B-OSE_Labeled_AE
event I-OSE_Labeled_AE
. O

The O
majority O
of O
these O
events O
occurred O
in O
patients O
who O
received O
cisplatin/5-FU O
, O
with O
or O
without O
cetuximab O
as O
follows O
: O
11 O
% O
and O
12 O
% O
in O
patients O
who O
received O
cisplatin/5-FU O
with O
or O
without O
cetuximab O
, O
respectively O
, O
and O
6 O
% O
or O
4 O
% O
in O
patients O
who O
received O
carboplatin/5-FU O
with O
or O
without O
cetuximab O
, O
respectively O
. O

In O
both O
arms O
, O
the O
incidence O
of O
cardiovascular B-OSE_Labeled_AE
events I-OSE_Labeled_AE
was O
higher O
in O
the O
cisplatin O
with O
5-FU O
containing O
subgroup O
. O

Death B-NonOSE_AE
attributed O
to O
cardiovascular B-NonOSE_AE
event I-NonOSE_AE
or O
sudden B-NonOSE_AE
death I-NonOSE_AE
was O
reported O
in O
3 O
% O
of O
the O
patients O
in O
the O
cetuximab O
plus O
platinum-based O
therapy O
with O
5-FU O
arm O
and O
2 O
% O
in O
the O
platinum-based O
chemotherapy O
with O
5-FU O
alone O
arm O
. O

Colorectal O
Cancer O
Study O
4 O
: O
EU-Approved O
Cetuximab O
in O
Combination O
with O
FOLFIRI O
Study O
4 O
used O
EU-approved O
cetuximab O
. O

U.S.-licensed O
Erbitux O
provides O
approximately O
22 O
% O
higher O
exposure O
to O
cetuximab O
relative O
to O
the O
EU-approved O
cetuximab O
. O

The O
data O
provided O
below O
for O
Study O
4 O
is O
consistent O
in O
incidence O
and O
severity O
of O
adverse O
reactions O
with O
those O
seen O
for O
Erbitux O
in O
this O
indication O
. O

The O
tolerability O
of O
the O
recommended O
dose O
is O
supported O
by O
safety O
data O
from O
additional O
studies O
of O
Erbitux O
[ O
see O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

Table O
4 O
contains O
selected O
adverse O
reactions O
in O
667 O
patients O
with O
K-Ras O
wild-type O
, O
EGFR-expressing O
, O
metastatic B-Not_AE_Candidate
colorectal I-Not_AE_Candidate
cancer I-Not_AE_Candidate
receiving O
EU-approved O
cetuximab O
plus O
FOLFIRI O
or O
FOLFIRI O
alone O
in O
Study O
4 O
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
. O

Cetuximab O
was O
administered O
at O
the O
recommended O
dose O
and O
schedule O
( O
400 O
mg/m O
2 O
initial O
dose O
, O
followed O
by O
250 O
mg/m O
2 O
weekly O
) O
. O

Patients O
received O
a O
median O
of O
26 O
infusions O
( O
range O
1-224 O
) O
. O

Table O
4 O
: O
Incidence O
of O
Selected O
Adverse O
Reactions O
Occurring O
in O
> O
=10 O
% O
of O
Patients O
with O
K-Ras O
Wild-type O
and O
EGFR-expressing O
, O
Metastatic O
Colorectal O
Cancera O
Body O
System O
Preferred O
Term O
EU-Approved O
Cetuximab O
plus O
FOLFIRI O
( O
n=317 O
) O
FOLFIRI O
Alone O
( O
n=350 O
) O
Grades O
1-4 O
b O
Grades O
3 O
and O
4 O
Grades O
1-4 O
Grades O
3 O
and O
4 O
% O
of O
Patients O
a O
Adverse O
reactions O
occurring O
in O
at O
least O
10 O
% O
of O
Erbitux O
combination O
arm O
with O
a O
frequency O
at O
least O
5 O
% O
greater O
than O
that O
seen O
in O
the O
FOLFIRI O
arm O
. O

b O
Adverse O
reactions O
were O
graded O
using O
the O
NCI O
CTC O
, O
V O
2.0 O
. O
c O
Infusion B-OSE_Labeled_AE
related I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
is O
defined O
as O
any O
event O
meeting O
the O
medical O
concepts O
of O
allergy B-OSE_Labeled_AE
/ O
anaphylaxis B-OSE_Labeled_AE
at O
any O
time O
during O
the O
clinical O
study O
or O
any O
event O
occurring O
on O
the O
first O
day O
of O
dosing O
and O
meeting O
the O
medical O
concepts O
of O
dyspnea B-OSE_Labeled_AE
and O
fever B-OSE_Labeled_AE
or O
by O
the O
following O
events O
using O
MedDRA O
preferred O
terms O
: O
`` O
acute B-OSE_Labeled_AE
myocardial I-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
`` O
, O
`` O
angina B-OSE_Labeled_AE
pectoris I-OSE_Labeled_AE
`` O
, O
`` O
angioedema B-OSE_Labeled_AE
`` O
, O
`` O
autonomic B-OSE_Labeled_AE
seizure I-OSE_Labeled_AE
`` O
, O
`` O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
`` O
, O
`` O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
`` O
, O
`` O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
`` O
, O
`` O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
`` O
, O
`` O
cardiopulmonary B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
`` O
, O
`` O
cardiovascular B-OSE_Labeled_AE
insufficiency I-OSE_Labeled_AE
`` O
, O
`` O
clonus B-OSE_Labeled_AE
`` O
, O
`` O
convulsion B-OSE_Labeled_AE
`` O
, O
`` O
coronary B-OSE_Labeled_AE
no I-OSE_Labeled_AE
- I-OSE_Labeled_AE
reflow I-OSE_Labeled_AE
phenomenon I-OSE_Labeled_AE
`` O
, O
`` O
epilepsy O
'' O
, O
`` O
hypertension B-OSE_Labeled_AE
`` O
, O
`` O
hypertensive B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
`` O
, O
`` O
hypertensive B-OSE_Labeled_AE
emergency I-OSE_Labeled_AE
`` O
, O
`` O
hypotension B-OSE_Labeled_AE
`` O
, O
`` O
infusion B-OSE_Labeled_AE
related I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
`` O
, O
`` O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
`` O
, O
`` O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
`` O
, O
`` O
myocardial B-OSE_Labeled_AE
ischaemia I-OSE_Labeled_AE
`` O
, O
" B-OSE_Labeled_AE
prinzmetal I-OSE_Labeled_AE
angina I-OSE_Labeled_AE
" I-OSE_Labeled_AE
, O
`` O
shock B-OSE_Labeled_AE
`` O
, O
`` O
sudden B-OSE_Labeled_AE
death I-OSE_Labeled_AE
`` O
, O
`` O
syncope B-OSE_Labeled_AE
`` O
, O
or O
`` O
systolic B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
`` O
. O

d O
Acne B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
rash I-OSE_Labeled_AE
is O
defined O
by O
the O
events O
using O
MedDRA O
preferred O
terms O
and O
included O
`` O
acne B-OSE_Labeled_AE
`` O
, O
`` O
acne B-OSE_Labeled_AE
pustular I-OSE_Labeled_AE
`` O
, O
`` O
butterfly B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
`` O
, O
`` O
dermatitis B-OSE_Labeled_AE
acneiform I-OSE_Labeled_AE
`` O
, O
`` O
drug B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
with I-OSE_Labeled_AE
eosinophilia I-OSE_Labeled_AE
and I-OSE_Labeled_AE
systemic I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
`` O
, O
`` O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
`` O
, O
`` O
erythema B-OSE_Labeled_AE
`` O
, O
`` O
exfoliative B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
`` O
, O
`` O
folliculitis B-OSE_Labeled_AE
`` O
, O
`` O
genital B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
`` O
, O
`` O
mucocutaneous B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
`` O
, O
`` O
pruritus B-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
erythematous I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
follicular I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
generalized I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
macular I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
maculopapular I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
maculovesicular I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
morbilliform I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
papular I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
papulosquamous I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
pruritic I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
pustular I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
rubelliform I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
scarlatiniform I-OSE_Labeled_AE
`` O
, O
`` O
rash B-OSE_Labeled_AE
vesicular I-OSE_Labeled_AE
`` O
, O
`` O
skin B-OSE_Labeled_AE
exfoliation I-OSE_Labeled_AE
`` O
, O
`` O
skin B-OSE_Labeled_AE
hyperpigmentation I-OSE_Labeled_AE
`` O
, O
`` O
skin B-OSE_Labeled_AE
plaque I-OSE_Labeled_AE
`` O
, O
`` O
telangiectasia B-OSE_Labeled_AE
`` O
, O
or O
`` O
xerosis B-OSE_Labeled_AE
`` O
. O

Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
49 O
31 O
42 O
24 O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
Conjunctivitis B-OSE_Labeled_AE
18 O
< O
1 O
3 O
0 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
66 O
16 O
60 O
10 O
Stomatitis B-OSE_Labeled_AE
31 O
3 O
19 O
1 O
Dyspepsia B-OSE_Labeled_AE
16 O
0 O
9 O
0 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
Infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
Reaction I-OSE_Labeled_AE
c O
14 O
2 O
< O
1 O
0 O
Pyrexia B-OSE_Labeled_AE
26 O
1 O
14 O
1 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Paronychia B-OSE_Labeled_AE
20 O
4 O
< O
1 O
0 O
Investigations B-NonOSE_AE
Weight B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
15 O
1 O
9 O
1 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Anorexia B-OSE_Labeled_AE
30 O
3 O
23 O
2 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Acne B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
Rash I-OSE_Labeled_AE
d O
86 O
18 O
13 O
< O
1 O
Rash B-OSE_Labeled_AE
44 O
9 O
4 O
0 O
Dermatitis B-OSE_Labeled_AE
Acneiform I-OSE_Labeled_AE
26 O
5 O
< O
1 O
0 O
Dry B-OSE_Labeled_AE
Skin I-OSE_Labeled_AE
22 O
0 O
4 O
0 O
Acne B-OSE_Labeled_AE
14 O
2 O
0 O
0 O
Pruritus B-OSE_Labeled_AE
14 O
0 O
3 O
0 O
Palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
plantar I-OSE_Labeled_AE
Erythrodysesthesia I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
19 O
4 O
4 O
< O
1 O
Skin B-OSE_Labeled_AE
Fissures I-OSE_Labeled_AE
19 O
2 O
1 O
0 O
Erbitux O
Monotherapy O
Table O
5 O
contains O
selected O
adverse O
reactions O
in O
242 O
patients O
with O
K-Ras O
wild-type O
, O
EGFR-expressing O
, O
metastatic B-Not_AE_Candidate
colorectal I-Not_AE_Candidate
cancer I-Not_AE_Candidate
who O
received O
best O
supportive O
care O
( O
BSC O
) O
alone O
or O
with O
Erbitux O
in O
Study O
5 O
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
. O

Erbitux O
was O
administered O
at O
the O
recommended O
dose O
and O
schedule O
( O
400 O
mg/m O
2 O
initial O
dose O
, O
followed O
by O
250 O
mg/m O
2 O
weekly O
) O
. O

Patients O
received O
a O
median O
of O
17 O
infusions O
( O
range O
1-51 O
) O
. O

Table O
5 O
: O
Incidence O
of O
Selected O
Adverse O
Reactions O
Occurring O
in O
> O
=10 O
% O
of O
Patients O
with O
K-Ras O
Wild-type O
, O
EGFR-expressing O
, O
Metastatic O
Colorectal O
Cancer O
Treated O
with O
Erbitux O
Monotherapya O
Body O
System O
Preferred O
Term O
Erbitux O
plus O
BSC O
( O
n=118 O
) O
BSC O
alone O
( O
n=124 O
) O
Grades O
1-4 O
b O
Grades O
3 O
and O
4 O
Grades O
1-4 O
Grades O
3 O
and O
4 O
% O
of O
Patients O
a O
Adverse O
reactions O
occurring O
in O
at O
least O
10 O
% O
of O
Erbitux O
plus O
BSC O
arm O
with O
a O
frequency O
at O
least O
5 O
% O
greater O
than O
that O
seen O
in O
the O
BSC O
alone O
arm O
. O

b O
Adverse O
reactions O
were O
graded O
using O
the O
NCI O
CTC O
, O
V O
2.0 O
. O
c O
Infusion B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
is O
defined O
as O
any O
event O
( O
chills B-OSE_Labeled_AE
, O
rigors B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
, O
bronchospasm B-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
tightness I-OSE_Labeled_AE
, O
swelling B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
flushing B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
, O
tremors B-OSE_Labeled_AE
, O
shaking B-OSE_Labeled_AE
, O
drug B-OSE_Labeled_AE
fever I-OSE_Labeled_AE
, O
or O
other O
hypersensitivity B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
) O
recorded O
by O
the O
investigator O
as O
infusion-related O
. O

Dermatology B-NonOSE_AE
/ I-NonOSE_AE
Skin I-NonOSE_AE
Rash B-OSE_Labeled_AE
/ O
Desquamation B-OSE_Labeled_AE
95 O
16 O
21 O
1 O
Dry B-OSE_Labeled_AE
Skin I-OSE_Labeled_AE
57 O
0 O
15 O
0 O
Pruritus B-OSE_Labeled_AE
47 O
2 O
11 O
0 O
Other B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Dermatology I-OSE_Labeled_AE
35 O
0 O
7 O
2 O
Nail B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
31 O
0 O
4 O
0 O
Constitutional B-NonOSE_AE
Symptoms I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
91 O
31 O
79 O
29 O
Fever B-OSE_Labeled_AE
25 O
3 O
16 O
0 O
Infusion B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
c O
18 O
3 O
0 O
0 O
Rigors B-OSE_Labeled_AE
, O
Chills B-OSE_Labeled_AE
16 O
1 O
3 O
0 O
Pain B-OSE_Labeled_AE
Pain B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Other I-OSE_Labeled_AE
59 O
18 O
37 O
10 O
Headache B-OSE_Labeled_AE
38 O
2 O
11 O
0 O
Bone B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
15 O
4 O
8 O
2 O
Pulmonary B-NonOSE_AE
Dyspnea B-OSE_Labeled_AE
49 O
16 O
44 O
13 O
Cough B-OSE_Labeled_AE
30 O
2 O
19 O
2 O
Gastrointestinal B-NonOSE_AE
Nausea B-OSE_Labeled_AE
64 O
6 O
50 O
6 O
Constipation B-OSE_Labeled_AE
53 O
3 O
38 O
3 O
Diarrhea B-OSE_Labeled_AE
42 O
2 O
23 O
2 O
Vomiting B-OSE_Labeled_AE
40 O
5 O
26 O
5 O
Stomatitis B-OSE_Labeled_AE
32 O
1 O
10 O
0 O
Other B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Gastrointestinal I-OSE_Labeled_AE
22 O
12 O
16 O
5 O
Dehydration B-OSE_Labeled_AE
13 O
5 O
3 O
0 O
Mouth B-OSE_Labeled_AE
Dryness I-OSE_Labeled_AE
12 O
0 O
6 O
0 O
Taste B-OSE_Labeled_AE
Disturbance I-OSE_Labeled_AE
10 O
0 O
5 O
0 O
Infection B-NonOSE_AE
Infection B-OSE_Labeled_AE
without I-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
38 O
11 O
19 O
5 O
Musculoskeletal B-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
14 O
3 O
6 O
0 O
Neurology B-NonOSE_AE
Neuropathy B-OSE_Labeled_AE
- I-OSE_Labeled_AE
sensory I-OSE_Labeled_AE
45 O
1 O
38 O
2 O
Insomnia B-OSE_Labeled_AE
27 O
0 O
13 O
0 O
Confusion B-OSE_Labeled_AE
18 O
6 O
10 O
2 O
Anxiety B-OSE_Labeled_AE
14 O
1 O
5 O
1 O
Depression B-OSE_Labeled_AE
14 O
0 O
5 O
0 O
Erbitux O
in O
Combination O
with O
Irinotecan O
The O
most O
frequently O
reported O
adverse O
reactions O
in O
354 O
patients O
treated O
with O
Erbitux O
plus O
irinotecan O
in O
clinical O
trials O
were O
acneiform B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
( O
88 O
% O
) O
, O
asthenia B-OSE_Labeled_AE
/ O
malaise B-OSE_Labeled_AE
( O
73 O
% O
) O
, O
diarrhea B-OSE_Labeled_AE
( O
72 O
% O
) O
, O
and O
nausea B-OSE_Labeled_AE
( O
55 O
% O
) O
. O

The O
most O
common O
Grades O
3-4 O
adverse O
reactions O
included O
diarrhea B-OSE_Labeled_AE
( O
22 O
% O
) O
, O
leukopenia B-OSE_Labeled_AE
( O
17 O
% O
) O
, O
asthenia B-OSE_Labeled_AE
/ O
malaise B-OSE_Labeled_AE
( O
16 O
% O
) O
, O
and O
acneiform B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
( O
14 O
% O
) O
. O

6.2 O
Immunogenicity O
As O
with O
all O
therapeutic O
proteins O
, O
there O
is O
potential O
for O
immunogenicity B-OSE_Labeled_AE
. O

An O
ELISA O
methodology O
was O
used O
to O
characterize O
the O
incidence O
of O
anti B-NonOSE_AE
- I-NonOSE_AE
cetuximab I-NonOSE_AE
antibodies I-NonOSE_AE
. O

In O
total O
, O
105 O
Erbitux-treated O
patients O
with O
at O
least O
one O
post-baseline O
blood O
sample O
( O
> O
=4 O
weeks O
post O
first O
administration O
) O
were O
assessed O
for O
the O
development O
of O
anti B-NonOSE_AE
- I-NonOSE_AE
cetuximab I-NonOSE_AE
binding I-NonOSE_AE
antibodies I-NonOSE_AE
and O
the O
incidence O
of O
treatment-emergent O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
cetuximab I-OSE_Labeled_AE
binding I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
was O
< O
5 O
% O
. O

The O
incidence O
of O
antibody B-NonOSE_AE
formation I-NonOSE_AE
is O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assay O
. O

Additionally O
, O
the O
observed O
incidence O
of O
antibody B-NonOSE_AE
( O
including O
neutralizing O
a O
ntibody B-NonOSE_AE
) I-NonOSE_AE
positivity I-NonOSE_AE
  I-NonOSE_AE
I-NonOSE_AE O
in O
an O
assay O
may O
be O
influenced O
by O
several O
factors O
including O
assay O
methodology O
, O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medications O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
Erbitux I-NonOSE_AE
with O
the O
incidence B-NonOSE_AE
of I-NonOSE_AE
antibodies I-NonOSE_AE
to I-NonOSE_AE
other I-NonOSE_AE
products I-NonOSE_AE
may O
be O
misleading O
. O

6.3 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post-approval O
use O
of O
Erbitux O
. O

Because O
these O
reactions O
are O
reported O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

* O
Aseptic B-OSE_Labeled_AE
meningitis I-OSE_Labeled_AE
* O
Mucosal B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
* O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
life-threatening O
and O
fatal B-NonOSE_AE
bullous B-OSE_Labeled_AE
mucocutaneous I-OSE_Labeled_AE
disease I-OSE_Labeled_AE

